Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors

2019 ◽  
Author(s):  
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Malignant Brain Tumors

LOCAL HYPERTHERMIA IN TREATMENT FOR MALIGNANT BRAIN TUMORS

2018 ◽  
Vol 64 (1) ◽  
pp. 54-61
Author(s):  
A. Ryabova ◽  
O. Gribova ◽  
V. Novikov ◽  
E. Choinzonov ◽  
Zh. Starceva ◽  
...  
Keyword(s):  
Experimental Data ◽  
Radiation Therapy ◽  
Brain Tumors ◽  
Tumor Cells ◽  
Combined Treatment ◽  
Complex Treatment ◽  
Local Hyperthermia ◽  
Malignant Brain Tumors ◽  
Sensitizing Effect ◽  
Methods Of Treatment

Unsatisfactory results of complex treatment for malignant brain tumors stimulate search of new effective methods of treatment. Radiation therapy is an integral part of the combined treatment but often does not influence lethally on resistant tumor cells. Thereby in recent decades there has been an active search for different modifiers, which can increase the sensitivity of tumors to chemotherapy and radiotherapy. One of the universal sensitizers is the local hyperthermia. Experimental data showed that the effect of high temperatures had both a direct damaging effect on tumor cells and a sensitizing effect. The literature review given in the article provides an overview of the existing methods of the local hyperthermia for brain tumors treatment.

Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children’s Cancer Group

2005 ◽  
Vol 23 (30) ◽  
pp. 7621-7631 ◽  
Author(s):  
J. Russell Geyer ◽  
Richard Sposto ◽  
Mark Jennings ◽  
James M. Boyett ◽  
Richard A. Axtell ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Induction Chemotherapy ◽  
Metastatic Disease ◽  
Response Rate ◽  
Residual Tumor ◽  
Study Entry ◽  
Receive Radiation Therapy ◽  
Malignant Brain Tumors ◽  
Significant Difference

Purpose To evaluate response rate, event-free survival (EFS), and toxicity of two chemotherapeutic regimens for treatment of children younger than 36 months with malignant brain tumors and to estimate control intervals without irradiation in children with no residual tumor after initial surgery and induction chemotherapy and with delayed irradiation in patients with residual tumor or metastatic disease at diagnosis. Patients and Methods Patients were randomly assigned to one of two regimens of induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide v vincristine, carboplatin, ifosfamide, and etoposide). Maintenance chemotherapy began after induction in children without progressive disease. Children with no residual tumors after induction therapy and no metastatic disease at diagnosis were not to receive radiation therapy unless their tumors progressed. Results Two hundred ninety-nine infants were enrolled. Forty-two percent of patients responded to induction chemotherapy. At 5 years from study entry, the EFS rate was 27% ± 3%, and the survival rate was 43% ± 3%. There was no significant difference between the two arms in terms of response rate or EFS. For medulloblastoma, supratentorial primitive neuroectodermal tumor, ependymoma, and rhabdoid tumors, 5-year EFS rates were 32% ± 5%, 17% ± 6%, and 32% ± 6%, and 14% ± 7%, respectively. Fifty-eight percent of patients who were alive 5 years after study entry had not received radiation therapy. Conclusion Intensified induction chemotherapy resulted in a high response rate of malignant brain tumors in infants. Survival was comparable to that of previous studies, and most patients who survived did not receive radiation therapy.

Radiation therapy for malignant brain tumors in infants less than 36 months old: Compliance and survival

2000 ◽  
Vol 48 (3) ◽  
pp. 180 ◽  
Author(s):  
M.L Tao ◽  
J.A Turner ◽  
J.R Geyer ◽  
B Donahue ◽  
R Sposto ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Malignant Brain Tumors

scholarly journals Effect of Lymphokine—activated Killer Cells with or without Radiation Therapy against Malignant Brain Tumors

1995 ◽  
Vol 35 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Kunio NAKAGAWA ◽  
Takao KAMEZAKI ◽  
Yasushi SHIBATA ◽  
Takashi TSUNODA ◽  
Kotoo MEGURO ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Malignant Brain Tumors

In vitro efficacy of recombinant diphtheria toxin–murine interleukin-4 immunoconjugate on mouse glioblastoma and neuroblastoma cell lines and the additive effect of radiation

2000 ◽  
Vol 9 (6) ◽  
pp. 1-6 ◽  
Author(s):  
Ki-Uk Kim ◽  
Daniel A. Vallera ◽  
Hsaio-Tzu Ni ◽  
Kwan H. Cho ◽  
Walter C. Low ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Cell Lines ◽  
Diphtheria Toxin ◽  
Cytotoxic Effect ◽  
Neuroblastoma Cell ◽  
Interleukin 4 ◽  
Treatment Modalities ◽  
Malignant Brain Tumors

Object The prognosis for patients with primary malignant brain tumors is poor despite aggressive treatment, and tumor recurrence is common regardless of the chosen therapy. Although multimodal treatment does not provide a cure, it is necessary to determine which treatment modalities have the greatest cytotoxic effect and can potentially prolong survival. Immunotoxin therapy is a novel approach for the treatment of tumors, and it has been successfully used in the central nervous system. Because the interleukin (IL)–4 receptor is commonly expressed on brain tumor cells, the purpose of this study was to evaluate the cytotoxic effect of using a modified diphtheria toxin–murine IL-4 (DT390-mIL4) immunoconjugate for the treatment of murine brain tumor cell lines and to determine whether the addition of radiation therapy could potentiate the effect of this agent. Methods Spontaneous murine glioblastoma (SMA-560) and two neuroblastoma (Neuro-2a and NB41A3) cell lines were treated using DT390-mIL4 at different concentrations, and the anti–mouse IL-4 monoclonal antibody (11B11) was used for blocking its cytotoxicity. Other SMA-560 and Neuro-2a cell lines were treated using 500 cGy of radiation 3 hours before DT390-mIL4 treatment. Cytotoxity was evaluated using a trypan blue viability assay. The immunoconjugate exhibited a dose-dependent cytotoxic effect with 50% inhibitory concentration values of 0.56 × 10−9 M in SMA-560, 1.28 × 10−9 M in Neuro-2a, and 0.95 × 10−10 M in NB41A3 cell lines. The cytotoxicity of DT390-mIL4 was specifically blocked by an excess of 11B11. Cytotoxicity was additive when the DT390-mIL4 at 10−9 M immunoconjugate administration was followed by radiation therapy. Conclusions These results indicate that the IL-4 receptor can be a target for diphtheria toxin fusion proteins and that radiation can potentiate the effects of DT390-mIL4. The development of multimodal approaches to treat malignant brain tumors with agents that have different mechanisms of action may be beneficial.

VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors

1990 ◽  
Vol 8 (2) ◽  
Author(s):  
RichardM. Hellman ◽  
JohnA. Calogero ◽  
BruceM. Kaplan
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Malignant Brain Tumors

Radiation Therapy of Malignant Brain Tumors

Neurosurgery ◽  
1978 ◽  
Vol 25 (CN_suppl_1) ◽  
pp. 397-402 ◽  
Author(s):  
William M. Wara ◽  
Glenn E. Sheline
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Malignant Brain Tumors
Sign in / Sign up

Export Citation Format

Share Document